Beta-blockers ‘prolong’ ovarian cancer patient survival
For the first time, researchers say they have demonstrated a benefit in overall survival among epithelial ovarian cancer patients receiving beta-blockers. (Source: Nursing Times Breaking News)
Source: Nursing Times Breaking News - August 24, 2015 Category: Nursing Source Type: news
Generic heart medication shown to prolong ovarian cancer patients' survival
(University of Texas M. D. Anderson Cancer Center) In a first-of-its-kind study, researchers demonstrate a benefit in overall survival among epithelial ovarian cancer patients receiving generic heart medications known as beta-blockers. Survival was shown to be greatest among those prescribed first-generation nonselective beta-blockers. According to The University of Texas MD Anderson Cancer Center investigators, the drugs block the effects of stress pathways involved in tumor growth and spread. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 24, 2015 Category: Global & Universal Source Type: news
Generic heart medication shown to prolong ovarian cancer patients' survival
In a first-of-its-kind study, researchers demonstrate a benefit in overall survival among epithelial ovarian cancer (EOC) patients receiving generic heart medications known as beta-blockers. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - August 23, 2015 Category: Cancer & Oncology Source Type: news
Seattle Cancer Center Using SMART Mesothelioma Treatment
A Toronto-based groundbreaking approach to treating mesothelioma has crossed the Canadian border and is now part of an innovative Seattle cancer treatment center.
Officials at the Swedish Cancer Institute in Seattle recently adopted the Surgery for Mesothelioma After Radiation Therapy (SMART) approach that originated at the Princess Margaret Cancer Center in Toronto.
The therapy is a significant shift from the traditional lower-dose, radiation-after-surgery method to a more high-intensity approach that has more than doubled the three-year survival rate for pleural mesothelioma patients.
Officials at the Swedish Cance...
Source: Asbestos and Mesothelioma News - July 27, 2015 Category: Environmental Health Authors: Tim Povtak Tags: Treatment & Doctors Source Type: news
UCLA study finds that a protein that helps suppress cancer fades as we age
Researchers at UCLA have found that a protein that serves as a suppressor of cancer diminishes in skin and mouth epithelial cells as the human body ages.
Dr. No-Hee Park, dean of the UCLA School of Dentistry, and his research team have been studying p53, a tumor suppressor protein known as “the guardian of the genome” because of its involvement in DNA repair, cell cycle regulation and cellular deterioration.
“Looking at ways to maintain levels of p53 as one ages may provide a therapeutic clue to preventing cancer development,” said Park, who is also a distinguished professor in the departments of dentistry and medi...
Source: UCLA Newsroom: Health Sciences - July 16, 2015 Category: Universities & Medical Training Source Type: news
UCLA and City of Hope scientists use nanoparticles to shut down mechanism that drives cancer growth
When scientists develop cancer therapies, they target the features that make the disease deadly: tumor growth, metastasis, recurrence and drug resistance. In epithelial cancers — cancers of the breast, ovaries, prostate, skin and bladder, which begin in the organs’ lining — these processes are controlled by a genetic program called epithelial–mesenchymal transition.
UCLA
Jeffrey Zink
Epithelial–mesenchymal transition is regulated by a protein called Twist, which means that Twist directly influences the development of cancer, its spread to other organs and its return after remission.
In a major step toward devel...
Source: UCLA Newsroom: Health Sciences - July 3, 2015 Category: Universities & Medical Training Source Type: news
Clinical Evaluation of ErbB-Targeted CAR T-Cells, Following Intracavity Delivery in Patients with ErbB-Expressing Solid Tumors
Adoptive cell therapy using gene-modified T-cells has achieved impressive results in the treatment of B-cell malignancies. However, the development of similar strategies to treat solid tumors raises challenges with respect to tumor antigen selection and the achievement of efficient T-cell homing, survival and sustained effector function within the tumor microenvironment. To address these challenges, we have developed a gene-modified cellular therapy called T4 immunotherapy. To generate T4 immunotherapy, autologous T-cells are engineered by retroviral transduction to co-express two transgenes: (1) a chimeric antigen recepto...
Source: Springer protocols feed by Cancer Research - June 26, 2015 Category: Cancer & Oncology Source Type: news
New screening technique could pick up twice as many women with ovarian cancer
(University College London) A new screening method can detect twice as many women with ovarian cancer as conventional strategies, according to the latest results from the largest trial of its kind led by UCL. The new method detected cancer in 86 percent of women with invasive epithelial ovarian cancer, whereas the conventional test used in previous trials or in clinical practice would have identified fewer than half of these women (41 percent or 48 percent respectively). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 4, 2015 Category: Cancer & Oncology Source Type: news
This Budding Scientist-Entrepreneur Puts The Girls-In-STEM Problem In New Perspective
There's no doubt that women tend to steer clear of careers in science and technology--the statistics simply don't lie.
Nor is there any doubt that the persistent gender disparity in STEM (science, technology, engineering, and math) fields represents a big problem for our competitiveness as a nation as well as for individual women.
But why are women underrepresented in STEM? Some say girls are deterred by an "implicit bias" that leads us to see science and math as "male" fields. Others point to research showing gender discrimination against women who apply for STEM jobs.
Sara Sakowitz, a 19-year-old freshman biomedical...
Source: Science - The Huffington Post - April 7, 2015 Category: Science Source Type: news
UK Study Shows Promise for Epithelioid Mesothelioma Patients
In this study, it accounted for 73 of the 103 cases — or 71.5 percent. Those generally responded best to treatment.
The one, two and five-year survival rates for epithelial types in the study were 94.5 percent, 76.5 percent and 30.7 percent, respectively.
The patients were from January 2004 to December 2013. Almost half still are alive, according to the study report. Median age of the patients was 64.7 years at time of surgery and 24 patients were older than 70.
The overall median survival was 32 months, considerably longer than the estimated 6-18 months that patients often survive in the U.S. if they don't find a mesot...
Source: Asbestos and Mesothelioma News - March 12, 2015 Category: Environmental Health Authors: Tim Povtak Tags: Treatment & Doctors Source Type: news
Chemotherapy and Improved Surgical Techniques Noted as Important Advancements in Treating Ovarian Cancer over the Last Two Decades
NCCN has published the 20th annual edition of the NCCN Guidelines® for Ovarian Cancer, one of the original NCCN Guidelines published in November 1996.
FORT WASHINGTON, PA - Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States and is the country's fifth most common cause of cancer mortality in women. In 2015, it is estimated that more than 21,000 new diagnoses and more than 14,000 deaths from this neoplasm will occur in the United States; less th... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - March 12, 2015 Category: Cancer & Oncology Source Type: news
Ovarian Cancer: Chemotherapy and Improved Surgical Techniques
Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States and is the country's fifth most common cause of cancer mortality in women. In 2015, it is estimated that more than 21,000 new diagnoses and more than 14,000 deaths from this neoplasm will occur in the United States; less than 40 percent of women with ovarian cancer are cured. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 9, 2015 Category: Science Source Type: news
Breakthrough in understanding how cancer cells metastasize
A protein commonly found in human cells could be an important switch that activates cancer cell metastasis, according to a new study. The finding focuses attention on a biological mechanism that until now was largely overlooked. The discovery of the protein's effect significantly expands our understanding of epithelial cancers such as breast and lung cancer. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 27, 2015 Category: Science Source Type: news
Breakthrough in understanding how cancer cells metastasize
(McGill University) A protein commonly found in human cells could be an important switch that activates cancer cell metastasis, according to a new study by researchers at the Montreal Neurological Institute and Hospital -- The Neuro at McGill University and the MUHC. The finding focuses attention on a biological mechanism that until now was largely overlooked. The discovery of the protein's effect significantly expands our understanding of epithelial cancers such as breast and lung cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 27, 2015 Category: Global & Universal Source Type: news
[Editors' Choice] RAS signaling unleashed in breast cancer
The GTPases RND1 and RAS cooperate to promote epithelial-to-mesenchymal transition and metastasis. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - January 23, 2015 Category: Science Authors: Nancy Gough (mailto:ngough at aaas.org) Source Type: news
